There are currently two FDA-approved treatments for adults and children infected with Zaire ebolavirus.
Inmazeb™, approved in October 2020, is a combination of three monoclonal antibodies. Ebanga™, approved in December 2020, is a single monoclonal antibody.
Monoclonal antibodies (mAbs) are proteins that behave like natural antibodies to prevent viruses from replicating. These mAbs bind to the Ebola virus’s glycoprotein and thus prevent the virus from entering the host cells. Both of these treatments were evaluated during the 2018-2020 Ebola outbreak in the Democratic Republic of the Congo. "Overall survival was much higher for patients receiving either of the two treatments that are now approved by the FDA. Neither Inmazeb™ nor Ebanga™ have been evaluated for efficacy against species other than Zaire ebolavirus."5